Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment
Hyde C, Wake B, Bryan S, Barton P, Fry-Smith A, Davenport C, Song F
Record ID 32002000361
English
Authors' objectives:
Although the use of intravenous fludarabine is already well established in its current licensed indication, this review considers whether this should be supported and further encouraged.
Authors' recommendations:
Based on the limited evidence available, intravenous fludarabine seems to be an effective second-line treatment for CLL. Whether fludarabine used in this way is an efficient use of healthcare resources is uncertain. The recent licensing of an oral preparation of fludarabine has implications for cost and patient acceptability. Its effectiveness, cost and cost-effectiveness will need to be assessed, as this could not be covered in this report.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1200
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.